Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus DEPO TESTOSTERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus DEPO TESTOSTERONE.
ANDROID-F vs DEPO-TESTOSTERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Testosterone binds to androgen receptors, activating gene transcription that promotes development of male secondary sexual characteristics, anabolic effects, and erythropoiesis.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
50-400 mg IM every 2-4 weeks
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
The terminal elimination half-life of testosterone cypionate after intramuscular injection is approximately 8 days, allowing for dosing every 2-4 weeks.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (90%) and in feces via bile (10%).
Category C
Category D/X
Androgen/Estrogen Combination
Androgen